Your search for esrd returned 16 results

End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.

The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…

Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

Sarilumab administered every 2 weeks is associated with similar improvements in physical function in adult patients with rheumatoid arthritis, compared with adalimumab.

Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.

The trial compares short- and long-term outcomes of Cimzia and Humira in RA

Uveitis should be suspected in patients with ankylosing spondylitis (AS) who have high lesion counts, antistreptolysin O (ASO) and circulating immune complex (CIC) titers

A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.

Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and “appeared similar regardless of methotrexate dose” in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.